Shilpa Medicare's Unit VI, at Bengaluru has receive EIR from USFDA

Shilpa Medicare, Unit VI, Dabaspet, Bengaluru, Karnataka, India has received EIR with VAI (Voluntary Action Indicated) classification, from USFDA, for the GMP inspection which was conducted from October 24 – 30, 2024.

This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms - Oral Dissolving Films and Transdermal Systems.

The Unit is already approved by EMA, Europe; MHRA, UK; SFDA, Saudi and TGA, Australia.

This Unit is currently supplying Oral Film products to US and other markets. Transdermal products have been filed in the European market.

At 11.15 am, Shilpa Medicare was trading at Rs. 938, up by 4.87%, with a volume of 0.11 lakh shares on the BSE.